Cipher Pharmaceuticals Inc. (CPH.TO)
Company Info
| ISIN | CA17253X1050 |
|---|---|
| CUSIP | 17253X105 |
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
Highlights
| Market Cap | CA$327.55M |
|---|---|
| EPS (TTM) | CA$1.25 |
| PE Ratio | 10.24 |
| Total Revenue (TTM) | CA$16.09M |
| Gross Profit (TTM) | CA$12.98M |
| EBITDA (TTM) | CA$9.44M |
| Year Range | CA$5.32 - CA$19.69 |
| Target Price | CA$18.08 |
| Short % | 0.07% |
| Short Ratio | 2.39 |
Share Price Chart
Loading data...
Compare to other instruments
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
Performance Chart
The chart shows the growth of an initial investment of CA$10,000 in Cipher Pharmaceuticals Inc., comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.
Returns By Period
Cipher Pharmaceuticals Inc. had a return of 149.10% year-to-date (YTD) and 154.61% in the last 12 months. Over the past 10 years, Cipher Pharmaceuticals Inc. had an annualized return of -1.16%, while the S&P 500 had an annualized return of 11.31%, indicating that Cipher Pharmaceuticals Inc. did not perform as well as the benchmark.
| Period | Return | Benchmark |
|---|---|---|
| Year-To-Date | 149.10% | 24.72% |
| 1 month | -19.06% | 2.30% |
| 6 months | 56.46% | 12.31% |
| 1 year | 154.61% | 32.12% |
| 5 years (annualized) | 62.29% | 13.81% |
| 10 years (annualized) | -1.16% | 11.31% |
Monthly Returns
The table below presents the monthly returns of CPH.TO, with color gradation from worst to best to easily spot seasonal factors. Returns are adjusted for dividends.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024 | 6.68% | 18.61% | 26.96% | -3.48% | 1.98% | -6.39% | 55.12% | 49.29% | -19.75% | -1.31% | 149.10% | ||
| 2023 | -10.68% | 10.79% | -13.16% | 3.03% | 13.82% | -7.75% | 4.20% | 6.45% | 7.32% | 2.59% | 44.72% | -12.20% | 44.27% |
| 2022 | -0.56% | 13.07% | 14.07% | -1.32% | 6.25% | -7.56% | -0.45% | 19.63% | 23.66% | -2.16% | 10.41% | 9.71% | 116.95% |
| 2021 | -3.23% | 2.22% | 40.22% | 0.78% | 3.08% | 11.94% | 2.00% | 39.22% | 3.76% | 14.48% | -29.25% | -1.12% | 90.32% |
| 2020 | -30.67% | -11.54% | -23.91% | 35.71% | 29.47% | -2.44% | 15.83% | -17.27% | -6.96% | -7.48% | -16.16% | 12.05% | -38.00% |
| 2019 | 11.70% | 1.57% | -27.84% | -0.00% | -3.57% | -2.96% | -11.45% | 11.21% | 8.53% | -15.00% | 1.68% | 23.97% | -12.28% |
| 2018 | -19.18% | 7.07% | -0.94% | -13.81% | -5.52% | -14.62% | -1.03% | 18.69% | -4.96% | -13.50% | -24.47% | -19.72% | -65.10% |
| 2017 | -3.06% | -3.16% | -0.00% | -3.26% | 26.07% | 1.60% | -5.09% | -3.88% | -8.65% | -8.84% | 15.47% | -2.00% | -0.00% |
| 2016 | -10.79% | 11.40% | -3.26% | 18.91% | 2.56% | -11.30% | -2.52% | -15.20% | -10.04% | -3.39% | -19.59% | 25.64% | -24.50% |
| 2015 | 4.24% | -18.16% | -19.73% | 9.24% | -1.92% | -13.18% | -0.37% | -33.77% | -29.69% | 9.09% | 13.33% | 6.05% | -61.25% |
| 2014 | 0.65% | 3.98% | -6.05% | 10.91% | -6.40% | 11.52% | 2.72% | 19.01% | 8.64% | 20.85% | 8.56% | 9.12% | 116.41% |
| 2013 | 8.00% | -9.26% | 43.67% | 3.69% | 15.07% | 13.10% | 48.21% | 32.10% | -32.37% | 25.60% | 10.00% | -10.93% | 209.60% |
Risk-Adjusted Performance
Risk-Adjusted Performance Rank
The current risk-adjusted rank of CPH.TO is 92, placing it in the top 8% of stocks on our website in terms of risk-adjusted performance. This ranking is based on the combined values of the indicators listed below.
Risk-Adjusted Performance Indicators
The charts below present risk-adjusted performance metrics for Cipher Pharmaceuticals Inc. (CPH.TO) and compare them to a chosen benchmark (^GSPC). These indicators evaluate an investment's returns against its associated risks.
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Worst Drawdowns
The table below displays the maximum drawdowns of the Cipher Pharmaceuticals Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the Cipher Pharmaceuticals Inc. was 97.90%, occurring on Mar 18, 2020. Recovery took 1117 trading sessions.
The current Cipher Pharmaceuticals Inc. drawdown is 27.33%.
Depth | Start | To Bottom | Bottom | To Recover | End | Total |
|---|---|---|---|---|---|---|
| -97.9% | Dec 29, 2014 | 1311 | Mar 18, 2020 | 1117 | Aug 29, 2024 | 2428 |
| -94.14% | Feb 15, 2006 | 679 | Oct 27, 2008 | 1179 | Jul 9, 2013 | 1858 |
| -71.62% | Feb 26, 2004 | 456 | Dec 6, 2005 | 35 | Jan 27, 2006 | 491 |
| -33.09% | Sep 17, 2013 | 10 | Sep 30, 2013 | 216 | Aug 11, 2014 | 226 |
| -33.07% | Sep 3, 2024 | 51 | Nov 13, 2024 | — | — | — |
Volatility
Volatility Chart
The current Cipher Pharmaceuticals Inc. volatility is 18.09%, representing the average percentage change in the investments's value, either up or down over the past month. The chart below shows the rolling one-month volatility.
Financials
Financial Performance
Valuation
The Valuation section provides an assessment of the market value of Cipher Pharmaceuticals Inc. compared to its peers in the Drug Manufacturers - Specialty & Generic industry.
PE Ratio
The chart displays the price to earnings (P/E) ratio for CPH.TO in comparison to other companies of the Drug Manufacturers - Specialty & Generic industry. Currently, CPH.TO has a PE value of 10.2. This PE value is considered to be low compared to the rest of the industry.PEG Ratio
The chart displays the price to earnings to growth (PEG) ratio for CPH.TO in comparison to other companies of the Drug Manufacturers - Specialty & Generic industry. Currently, CPH.TO has a PEG value of 0.0. This PEG ratio falls in the average range for the industry.Historical P/E Ratio Chart
The chart below displays the historical trend of the price-to-earnings (P/E) ratio for Cipher Pharmaceuticals Inc..
Loading data...
Income Statement
| TTM | |
|---|---|
| Revenue | |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
| Operating Expenses | |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
| Income | |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |